How many insider trades does FilingIQ track for ALEC?

FilingIQ tracks 455 Form 4 insider transactions for ALEC (Alector, Inc.), covering filings from Feb 11, 2019 onwards. 9 of those were filed in the last 90 days.

Are ALEC insiders net buyers or net sellers?

Across the full Form 4 history for ALEC, 7 transactions (2%) were open-market purchases and 240 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ALEC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ALEC in?

Alector, Inc. (ALEC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $279.43M.

ALEC insider trading

NasdaqGS Healthcare

Alector, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

455

Last 90 days

Buys / sells

2% / 53%

Market cap

$279.43M

About Alector, Inc.

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Company website: www.alector.com

ALEC insider activity at a glance

FilingIQ has scored 455 insider transactions for ALEC since Feb 11, 2019. The most recent filing in our index is dated Apr 16, 2026.

Across the full history, 7 open-market purchases and 240 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ALEC insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ALEC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding ALEC

Euclidean Capital LLC

$8.47M · 1.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for ALEC?: FilingIQ tracks 455 Form 4 insider transactions for ALEC (Alector, Inc.), covering filings from Feb 11, 2019 onwards. 9 of those were filed in the last 90 days.
Are ALEC insiders net buyers or net sellers?: Across the full Form 4 history for ALEC, 7 transactions (2%) were open-market purchases and 240 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ALEC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ALEC in?: Alector, Inc. (ALEC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $279.43M.

Methodology & sources

Every ALEC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.